TabsDetailsBasic DetailsDate: Thursday, February 6, 2014Type: PublicationMedical Product: RotaTeq, Rotarix, rotavirus vaccineHealth Outcome(s): intussusceptionDescription: This article describes the findings of a study conducted to evaluate the risk of intussusception associated with two Rotavirus vaccines, Rotateq (RV5) and Rotarix (RV1), in infants 5 to 30.9 weeks of age in the United States. Read More Materials: The New England Journal of Medicine, Volume 370. No 6, February 2014, Pages 503-512 DOI:10.1056/NEJMoa1303164Additional InformationInformationTime Period: 2004–2011Population / Cohort: All infants 5 to 30.9 weeks of ageData Source(s): Mini-Sentinel Distributed Database (MSDD)Related Assessment(s): Intussusception Risk After Rotavirus Vaccination in U.S. InfantsContributorsAuthor(s): W. Katherine Yih PhD, MPH; Tracy A. Lieu MD, MPH; Martin Kulldorff PhD; David Martin MD, MPH; Cheryl McMahill-Walraven PhD, MSW; Richard Platt MD, MSc; Nandini Selvam PhD, MPH; Mano Selvan PhD; Grace M. Lee MD, MPH; Michael Nguyen MDCorresponding Author: W. K. Yih, Department of Population Medicine, Harvard Pilgrim Healthcare Institute and Harvard Medical School, 401 Park Drive, Suite 401 East, Boston, MA 02215, U.S.A. E-Mail: katherine_yih@harvardpilgrim.org
